Recap: TG Therapeutics Q1 Earnings

 

Shares of TG Therapeutics TGTX remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share were down 43.75% year over year to ($0.69), which missed the estimate of ($0.49).

Revenue of $793,000 up by 1986.84% year over year, which beat the estimate of $650,000.

Looking Ahead

TG Therapeutics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 10, 2021

Time: 08:30 AM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/tgx/mediaframe/45063/indexl.html

Price Action

52-week high: $56.74

52-week low: $16.56

Price action over last quarter: down 5.92%

Company Description

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!